Answers are grounded in this paper and cite their sources.
Inclusion body myositis (IBM) is a progressive autoimmune myositis refractory to conventional immunosuppression, yet mechanisms sustaining chronic inflammation remain unresolved. Integrating comparative single-nucleus RNA sequencing, spatial transcriptomics, and orthogonal validation across autoimmune myositis, we identified ZNF683+IL7R+ cytotoxic tissue-resident memory T (TRM) cells with natural killer cell-like features enriched in IBM. Trajectory analysis positioned an early-disease ZBTB16+ cytotoxic T cell state upstream of ZNF683+IL7R+TRM. ZNF683 overexpression induced memory and natural killer cell-like transcriptional programs while attenuating glucocorticoid-response signatures, linking this program to treatment refractoriness. Ligand-receptor modeling nominated candidate targetable circuits involving IL-15-IL15RA, XCL1-XCR1, and HMGB1/CXCL12-CXCR4. Spatial transcriptomics localized ZNF683+TRM to stress-associated IBM niches. These findings define a disease-specific TRM-centered circuit linked to treatment refractoriness and candidate therapeutic vulnerabilities in IBM.
No takes yet. Share an insight, caveat, or question.
Reyes et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: